BioInvent

288 articles about BioInvent

• BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

  8/6/2021

  BioInvent International AB announced that it has entered into a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent's BI-1808, one of its proprietary anti-TNFR2 antibodies and MSD's anti-PD-1 therapy, KEYTRUDA in a Phase 1/2a clinical trial for patients with lung cancer and ovarian cancer.

• BioInvent receives notice of allowance in China for BI-1206 patent

  6/24/2021

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the China National Intellectual Property Administration has issued a notice of allowance, informing the company that a patent application relating to the anti-FcγRllB antibody BI-1206 is granted contingent on payment of the issue fee.

• BioInvent and Transgene receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors

  5/27/2021

  BioInvent International AB and Transgene announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.

• Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors

  5/27/2021

  Transgene and BioInvent International AB announce that their Investigational New Drug application for BT-001 has been granted by the U.S. Food and Drug Administration.

• Resolutions at BioInvent's Annual General Meeting 2021

  4/29/2021

  The Annual General Meeting of BioInvent International AB resolved to elect Vincent Ossipow as new Board member and to re-elect the Board members Kristoffer Bissessar, Dharminder Chahal, Thomas Hecht, Leonard Kruimer and Bernd Seizinger.

• BioInvent International AB: Interim report January-March 2021

  4/28/2021

  BioInvent continued to make strong clinical and financial progress in Q1 2021. Positive interim results from the Phase 1/2a study of BI-1206 in B-cell non-Hodgkin's lymphoma are very encouraging.

• BioInvent's partner Oncurious NV presents Phase I data on TB-403 in pediatric cancer

  4/12/2021

  BioInvent International AB announced that Oncurious NV has presented data from a phase I dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma at the annual meeting of the American Association for Cancer Research.

• BioInvent International's Annual Report 2020 published - Apr 08, 2021

  4/8/2021

  BioInvent International AB announced that the Annual Report for 2020 is published and available at the company's website, www.bioinvent.com.

• BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808

  4/7/2021

  BioInvent International AB announced that the U.S. Food and Drug Administration has approved the Investigational New Drug for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808.

• Change in the number of shares and votes in BioInvent International AB - Mar 31, 2021

  3/31/2021

  BioInvent International AB announced that the company's total number of shares as per March 31, 2021 amounts to 58,471,096 shares, corresponding to an equal number of votes.

• Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021

  3/23/2021

  With the resolution, a directed share issue of approximately SEK 962 million (approximately USD 116 million) will be completed according to plan.

• BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607 at AACR Annual Meeting 2021

  3/11/2021

  BI-1607 designed to boost efficacy and overcome patients' resistance to clinically validated antibody therapy

• BioInvent and Transgene has enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

  3/1/2021

  BioInvent International AB and Transgene announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic vaccinia virus BT-001 has been enrolled at Institut Bergonié.

• Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

  3/1/2021

  Transgene and BioInvent International AB announced that the first patient in a Phase I/IIa clinical trial of the novel dual mechanism-of-action oncolytic Vaccinia virus BT-001 has been enrolled at Institut Bergonié.

• BioInvent International Financial Statement January 1 - December 31, 2020

  2/23/2021

  BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base.

• BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients

  1/28/2021

  Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin's lymphoma patients who have relapsed after treatment with rituximab

• BioInvent has enrolled first patient in a Phase I/IIa trial of the first-in-class anti-TNFR2 antibody BI-1808 for the treatment of patients with solid tumors and CTCL

  1/26/2021

  BioInvent International AB ("BioInvent" or the "Company") (OMXS: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces the enrollment of the first patient in a Phase I/IIa,

• 

  Clinical Catch-Up: January 18-22

  1/25/2021

  With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. Read on to see.

• BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma

  1/20/2021

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy announces that it will host a Key Opinion Leader call on BI-1206 for relapsed or refractory Non-Hodgkin's Lymphoma on Thursday, January 28, 2021 at 11:30 a.m. Eastern Time.

• BioInvent streamlines agreement on anti-FcγRllB antibody, BI-1206, ahead of Phase I/II data

  1/11/2021

  BioInvent International AB announces it has restructured a clinical development agreement with Cancer Research UK, the world's leading cancer charity, for its unique anti-FcγRIIB antibody, BI-1206.